Key result
Trastuzumab-induced LV cardiotoxicity in HER2+ breast cancer patients was associated with significantly lower right ventricular fractional area change compared to controls (42% vs 47%, P=0.01).
Why the study?
What is the incidence and prognostic value of RV dysfunction in breast cancer patients developing LV cardiotoxicity during trastuzumab therapy?
Population
30 HER2+ female patients with breast cancer treated with trastuzumab who developed cardiotoxicity, mean age…
Comparison
Trastuzumab (± anthracycline) therapy vs 30 age-balanced precancer therapy and HER2+…
Design
Case-control
Follow-up
23 ± 15 months
Authors
Loading...
RV assessment may inform trastuzumab cardiotoxicity monitoring; leaves open prognostic impact on LVEF recovery.
Case-Control (n=60)
What is the incidence and prognostic value of RV dysfunction in breast cancer patients developing LV cardiotoxicity during trastuzumab therapy?
Absolute Event Rate: 42% vs 47%
p-value: p=0.01
Right ventricular dysfunction is frequent in breast cancer patients developing LV cardiotoxicity from trastuzumab and may be associated with reduced LVEF recovery.
Calleja et al. (2015) conducted a case-control in HER2+ breast cancer with cardiotoxicity (n=60). Trastuzumab-induced cardiotoxicity vs. Age-balanced precancer therapy and HER2+ breast cancer patients was evaluated on Right ventricular fractional area change (RV FAC) (p=0.01). Trastuzumab-induced LV cardiotoxicity in HER2+ breast cancer patients was associated with significantly lower right ventricular fractional area change compared to controls (42% vs 47%, P=0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: